Novo touts SGLT2-topping data for blockbuster Victoza

SGLT2 drugs may be in the diabetes spotlight thanks to recent data showing that one of them--Eli Lilly ($LLY) and Boehringer Ingelheim's Jardiance--could cut cardiovascular risks. But Novo Nordisk ($NVO), maker of GLP-1 superstar Victoza, is striking back with some new data of its own. The company has rolled out a new meta-analysis showing that its therapy beat out SGLT2s at reducing the blood sugar metric HbA1c. More from FiercePharmaMarketing

Suggested Articles

To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.